Skip to main content
DAEWOONG CO.,LTD logo

DAEWOONG CO.,LTD — Investor Relations & Filings

Ticker · 003090 ISIN · KR7003090008 KO Manufacturing
Open in API
Filings indexed 309 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country KR South Korea
Listing KO 003090

About DAEWOONG CO.,LTD

https://www.daewoong.co.kr

Daewoong Co., Ltd. is a holding company operating primarily in the biotechnology and healthcare sectors. Its core business, conducted through subsidiaries like Daewoong Pharmaceutical, involves the research, development, manufacturing, and commercialization of a broad range of pharmaceutical products. The company's portfolio includes prescription drugs, over-the-counter (OTC) medications, quasi-drugs, and active pharmaceutical ingredients (APIs). Daewoong focuses on developing innovative drugs, with established expertise in gastrointestinal and endocrine therapeutic areas. A key product in its global portfolio is Nabota, an FDA-approved botulinum toxin. The company emphasizes continuous R&D and engages in open collaboration to develop new healthcare solutions.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(자회사의 주요경영사항) (비만치료용 세마글루타이드(4주 장기지속형 주사제) 기술도입 계약 체결)
Regulatory Filings Classification · 72% confidence The document is a Korean regulatory announcement of a significant licensing contract (“투자판단 관련 주요경영사항”), detailing a technology-in contract for semaglutide. It is not a financial report, earnings release, board change, or M&A takeover document. Rather, it is a general corporate regulatory filing disclosing a material contract. Hence it falls under the fallback Regulatory Filings category (RNS).
2026-05-21 Korean
[기재정정]투자판단관련주요경영사항(자회사의 주요경영사항) (mRNA 기반 Epigenetic Reprogramming of Aging (ERA) 기술이전 계약 지위 승계)
Regulatory Filings Classification · 85% confidence The document is a Korean regulatory “정정신고(보고)” (correction report) for an earlier “투자판단 관련 주요경영사항” (material investment‐decision disclosure) concerning the succession of contract rights. It is a standalone exchange disclosure of a material corporate action (license contract assignment), not a financial statement report, earnings release, board change, or other specific category. It does not present full financial statements or serve as a notice of dividend, proxy, or share issuance. Therefore, it defaults to the general Regulatory Filings category.
2026-05-20 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 98% confidence The document is titled “분기보고서” (Korean for “Quarterly Report”) for the first quarter of the 67th fiscal year, covering the period January 1 to March 31, 2026. It contains full financial and operational details typical of an interim/quarterly filing, not merely an announcement or summary. Therefore, it matches the definition of an Interim / Quarterly Report. Q1 2026
2026-05-15 Korean
투자판단관련주요경영사항(자회사의 주요경영사항) (INV008(15PGDH 저해제) 기술도입 계약 체결)
Regulatory Filings Classification · 75% confidence The document is a Korean regulatory announcement disclosing a material technology license and development contract (INV-008 15-PGDH inhibitor) entered by a subsidiary. It does not contain financial statements, earnings metrics, dividend details, management changes, or fundraising/financing transactions. It is neither a report (e.g., annual/interim) nor a financial supplement but a standard material contract disclosure. It therefore falls into the miscellaneous Regulatory Filings category (RNS).
2026-05-12 Korean
투자판단관련주요경영사항(자회사의 주요경영사항) (mRNA 기반 Epigenetic Reprogramming of Aging (ERA) 기술이전 계약 지위 승계)
Board/Management Information Classification · 95% confidence The document is a detailed announcement regarding a significant business transaction involving the succession of contractual rights related to a technology license agreement. It includes specifics about the contract, counterparties, dates, financial terms, and board resolution details. The content focuses on a major management decision impacting investment judgment rather than financial results, audit, or regulatory filings. It is not a full financial report, earnings release, or regulatory certification. The document is an announcement of a major management event related to the company's business activities and investment decisions, fitting the category of Board/Management Information (MANG). The document length is 2245 characters, which is relatively short but contains substantive information about a management decision rather than a mere report publication or regulatory filing. Therefore, the best classification is MANG with high confidence.
2026-05-07 Korean
투자판단관련주요경영사항(자회사의 주요경영사항) (펙수클루정(Fexuclue)의 적응증 추가 국내 품목허가 승인(헬리코박터파일로리 제균을 위한 항생제 병용요법))
Board/Management Information Classification · 95% confidence The document is a notification about a significant business event related to the approval of a new indication for a pharmaceutical product (Fexuclue) by a regulatory authority (Korean Ministry of Food and Drug Safety). It includes details such as approval dates, product information, and future plans. The document is short (1546 characters) and focuses on a specific corporate event rather than financial data or comprehensive reporting. It is not an annual or interim report, earnings release, or audit report. It is a typical example of an announcement of a major management or business event relevant to investors, which fits the category of 'Capital/Financing Update' or 'Management Information'. However, since it is about a significant business event related to investment judgment and major management matters, the best fit is 'Management Information' (MANG).
2026-04-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.